Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. RXST
RXST logo

RXST Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
7.660
Open
7.450
VWAP
7.52
Vol
370.11K
Mkt Cap
302.48M
Low
7.415
Amount
2.78M
EV/EBITDA(TTM)
--
Total Shares
41.27M
EV
74.45M
EV/OCF(TTM)
--
P/S(TTM)
2.23
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
Show More

Events Timeline

(ET)
2026-02-25
16:40:00
Sees FY26 Operating Expenses at $150M-$160M
select
2026-02-25
16:40:00
RxSight Reports Q4 Revenue of $32.61M, Exceeding Expectations
select
2026-01-12 (ET)
2026-01-12
09:00:00
Morgan Stanley Maintains RxSight Price Target at $10
select
2026-01-11 (ET)
2026-01-11
14:20:00
Company Appoints Mark Wilterding as CFO Effective January 11, 2026
select

News

seekingalpha
9.5
02-26seekingalpha
RxSight, Inc. Reports Q4 2025 Earnings with Strategic Insights
  • Sales Performance Review: RxSight reported Q4 2025 sales of $32.6 million, a 19% year-over-year decline primarily due to lower LDD sales, although LAL sales accounted for 86% of total sales, indicating strong demand for its core products.
  • Financial Condition Analysis: The company recorded a net loss of $9.2 million in Q4 2025, translating to a loss of $0.22 per share, and while SG&A expenses decreased by 2% year-over-year, the overall financial performance remains under pressure, reflecting intensified market competition and rising costs.
  • Future Outlook Guidance: Management anticipates 2026 revenue between $120 million and $135 million, implying a year-over-year decline of approximately 5% at the midpoint, with gross margin guidance set at 70% to 72%, demonstrating a cautious approach to the future market environment.
  • Strategic Development Direction: Management emphasized a focus on enhancing LAL utilization among existing customers and building relationships with key opinion leaders in international markets to support future sales growth, despite the risks associated with declining LDD sales.
seekingalpha
9.5
02-25seekingalpha
RxSight Issues 2026 Financial Guidance with Q4 Results
  • Earnings Highlights: RxSight reported a Q4 non-GAAP EPS of -$0.03, beating expectations by $0.17, indicating an improvement in profitability despite an 18.9% year-over-year revenue decline to $32.6 million, reflecting ongoing market demand challenges.
  • 2026 Financial Guidance: The company projects 2026 revenue between $120 million and $135 million, reflecting lower year-over-year LDD placements, which highlights the challenges in the market environment and a cautious outlook for future growth.
  • Gross Margin Expectations: The anticipated gross margin for 2026 is set at 70% to 72%, primarily driven by increased per-unit manufacturing costs, which could impact overall profitability, especially with declining production volumes.
  • Operating Expense Outlook: The company expects operating expenses for 2026 to range from $150 million to $160 million, with non-cash stock-based compensation expenses projected at $30 million to $32 million, indicating pressure on cost control while also reflecting a commitment to future investments.
Benzinga
2.0
01-12Benzinga
U.S. Stocks Mixed; Day One Biopharmaceuticals Shares Surge 20%
  • Mixed Market Performance: U.S. stocks exhibited mixed results on Monday, with the Nasdaq Composite gaining over 50 points and rising 0.29%, while the Dow Jones fell 0.19% to 49,411.94, indicating market volatility and investor caution.
  • Biopharma Surge: Day One Biopharmaceuticals Inc (NASDAQ:DAWN) shares surged 20% to $10.77 after reporting a projected 2025 OJEMDA net product revenue of $155.4 million, a 172% year-over-year increase, highlighting strong market demand and growth potential.
  • FDA Response Impact: Atara Biotherapeutics Inc (NASDAQ:ATRA) shares plummeted 53% to $6.41 following a Complete Response Letter from the FDA citing concerns over clinical trial adequacy, raising investor worries about the company's future prospects.
  • Sector Sentiment Fluctuations: Financial stocks dipped by 1.1% while consumer staples rose by 1%, reflecting differing investor confidence across sectors, which may influence future investment strategies and market trends.
Benzinga
7.5
01-12Benzinga
Planet Labs PBC Secures Nine-Figure Deal with Swedish Armed Forces, Shares Surge 7%
  • Stock Surge: Planet Labs PBC's announcement of a multi-year nine-figure agreement with the Swedish Armed Forces led to a 7% increase in share price to $24.29 on Monday, reflecting strong market confidence in the company's long-term contracts.
  • Revenue Outlook Boost: Day One Biopharmaceuticals Inc reported preliminary 2025 OJEMDA net product revenue of $155.4 million, up 172% year-over-year, indicating robust growth potential in the biopharmaceutical sector that may attract more investor interest.
  • Market Dynamics: Amid a broader decline in U.S. stocks, Wheels Up Experience Inc saw its shares jump 30.2% to $0.89, suggesting a market reassessment of its business model, potentially providing support for future financing and expansion.
  • Increased Demand for Safe Assets: Growing concerns about Federal Reserve independence have led investors to shift towards safe-haven assets like gold, driving up precious metals stocks, which reflects market sensitivity to economic uncertainties and a preference for secure investments.
NASDAQ.COM
9.5
01-11NASDAQ.COM
RxSight Expects Q4 2025 Revenue of $32.6 Million, Appoints CFO
  • Revenue Forecast Upgrade: RxSight anticipates Q4 2025 revenue to reach approximately $32.6 million, exceeding analysts' expectations of $27.53 million, indicating strong market performance and growth potential for the company.
  • Annual Revenue Outlook: Preliminary unaudited revenue for fiscal year 2025 is expected to be around $134.5 million, up from the November guidance of $125 million to $130 million, reflecting robust business growth and increased market demand.
  • Executive Appointment: The company has appointed Mark Wilterding as Chief Financial Officer, effective January 11, 2026, bringing over 25 years of financial leadership experience that will provide valuable industry insights and strategic direction.
  • Financial Reporting Schedule: RxSight plans to announce audited full-year financial results and 2026 guidance in conjunction with its Q4 earnings release, expected to provide investors with clearer future outlooks.
Globenewswire
9.5
01-11Globenewswire
RxSight Reports $134.5M Revenue for 2025, Announces CFO Transition
  • Revenue Growth: Preliminary unaudited revenue for 2025 is expected to be approximately $134.5 million, exceeding prior guidance of $125 to $130 million, indicating strong performance in the ophthalmic medical device market.
  • Procedure Volume Increase: The sale of 28,611 Light Adjustable Lenses (LAL) in Q4 represents a 10% increase compared to Q3 2025, reflecting positive progress in surgical volume recovery.
  • Device Installation Expansion: As of December 31, 2025, the company has installed 1,134 Light Delivery Devices (LDD), which not only enhances market penetration but also lays a solid foundation for future growth.
  • Executive Transition: Mark Wilterding has been appointed Chief Financial Officer effective January 11, 2026, and with his extensive experience in Medtech, he is expected to drive further advancements in financial management and operational excellence for the company.
Wall Street analysts forecast RXST stock price to rise
9 Analyst Rating
Wall Street analysts forecast RXST stock price to rise
1 Buy
6 Hold
2 Sell
Hold
Current: 0.000
sliders
Low
8.00
Averages
10.25
High
14.00
Current: 0.000
sliders
Low
8.00
Averages
10.25
High
14.00
Stifel
Thomas Stephan
Hold
downgrade
$10 -> $9
AI Analysis
2026-03-09
Reason
Stifel
Thomas Stephan
Price Target
$10 -> $9
AI Analysis
2026-03-09
downgrade
Hold
Reason
Stifel analyst Thomas Stephan lowered the firm's price target on RxSight to $9 from $10 and keeps a Hold rating on the shares. The firm updated models across its medical technology and supplies coverage following Q4 reporting from the group.
UBS
Danielle Antalffy
Neutral
maintain
$8 -> $9
2026-02-26
Reason
UBS
Danielle Antalffy
Price Target
$8 -> $9
2026-02-26
maintain
Neutral
Reason
UBS analyst Danielle Antalffy raised the firm's price target on RxSight to $9 from $8 and keeps a Neutral rating on the shares. The lower 2026 outlook should limit downside risk, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for RXST
Unlock Now

Valuation Metrics

The current forward P/E ratio for Rxsight Inc (RXST.O) is -9.28, compared to its 5-year average forward P/E of -27.24. For a more detailed relative valuation and DCF analysis to assess Rxsight Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-27.24
Current PE
-9.28
Overvalued PE
1.34
Undervalued PE
-55.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-26.57
Current EV/EBITDA
-4.19
Overvalued EV/EBITDA
3.00
Undervalued EV/EBITDA
-56.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
8.09
Current PS
3.41
Overvalued PS
11.68
Undervalued PS
4.50

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

list of stocks beat suited for sell put
Intellectia · 13 candidates
Relative Vol: >= 1.50Current Ratio: >= 1.50Debt Equity: <= 0.500Weekly Average Turnover: >= 2,000,000Is Optionable: TrueOption Sentiments: Bullish
Ticker
Name
Market Cap$
top bottom
OR logo
OR
OR Royalties Inc
8.14B
GNTX logo
GNTX
Gentex Corp
5.20B
CGON logo
CGON
CG Oncology Inc
4.61B
SII logo
SII
Sprott Inc
3.27B
PLAB logo
PLAB
Photronics Inc
2.14B
UAMY logo
UAMY
United States Antimony Corp
1.28B
show me these stocks
Intellectia · 24 candidates
Price: $0.05 - $20.00Relative Vol: >= 1.50Beta: HighRiskWeekly Average Turnover: >= 1,000,000Shares Outstanding: <= 50,000,000
Ticker
Name
Market Cap$
top bottom
KRNT logo
KRNT
Kornit Digital Ltd
649.13M
FCEL logo
FCEL
Fuelcell Energy Inc
446.34M
RXST logo
RXST
Rxsight Inc
409.11M
TARA logo
TARA
Protara Therapeutics Inc
309.20M
OSS logo
OSS
One Stop Systems Inc
286.10M
MEI logo
MEI
Methode Electronics Inc
267.33M
I mean the lowest priced stock
Intellectia · 24 candidates
Price: <= $10.00Relative Vol: >= 1.50Gap Pattern: GapDownMoving Average Relationship: PriceCrossAboveMA5Candlestick Pattern: InverseHeadAndShoulder, WhiteCandlestick
Ticker
Name
Market Cap$
top bottom
RXST logo
RXST
Rxsight Inc
409.11M
SY logo
SY
So-Young International Inc
305.89M
OABI logo
OABI
OmniAb Inc
289.35M
FNKO logo
FNKO
Funko Inc
211.27M
NAMM logo
NAMM
Namib Minerals
121.31M
MGLD logo
MGLD
Marygold Companies Inc
53.85M
What stock to buy for short term?
Intellectia · 28 candidates
Relative Vol: >= 1.50Beta: HighRiskWeekly Average Turnover: >= 1,000,000Rsi 14: 40 - 60Week Price Change Pct: >= $2.00
Ticker
Name
Market Cap$
top bottom
ARM logo
ARM
Arm Holdings PLC
120.87B
NU logo
NU
Nu Holdings Ltd
83.54B
MOG.A logo
MOG.A
Moog Inc
9.94B
GME logo
GME
GameStop Corp
9.72B
QS logo
QS
Quantumscape Corp
6.64B
TGS logo
TGS
Transportadora de Gas del Sur SA
4.61B

Whales Holding RXST

R
RA Capital Management, L.P.
Holding
RXST
-0.49%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Rxsight Inc (RXST) stock price today?

The current price of RXST is 7.48 USD — it has increased 2.05

What is Rxsight Inc (RXST)'s business?

RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.

What is the price predicton of RXST Stock?

Wall Street analysts forecast RXST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXST is10.25 USD with a low forecast of 8.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Rxsight Inc (RXST)'s revenue for the last quarter?

Rxsight Inc revenue for the last quarter amounts to 32.61M USD, decreased -18.91

What is Rxsight Inc (RXST)'s earnings per share (EPS) for the last quarter?

Rxsight Inc. EPS for the last quarter amounts to -0.22 USD, increased 46.67

How many employees does Rxsight Inc (RXST). have?

Rxsight Inc (RXST) has 461 emplpoyees as of March 16 2026.

What is Rxsight Inc (RXST) market cap?

Today RXST has the market capitalization of 302.48M USD.